Cite
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
MLA
Blackhall, Fiona H., et al. “A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 5, no. 8, Aug. 2010, pp. 1285–88. EBSCOhost, https://doi.org/10.1097/JTO.0b013e3181e3a2d1.
APA
Blackhall, F. H., O’brien, M., Schmid, P., Nicolson, M., Taylor, P., Milenkova, T., Kennedy, S. J., & Thatcher, N. (2010). A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 5(8), 1285–1288. https://doi.org/10.1097/JTO.0b013e3181e3a2d1
Chicago
Blackhall, Fiona H, Mary O’brien, Peter Schmid, Marianne Nicolson, Paul Taylor, Tsveta Milenkova, Sarah J Kennedy, and Nick Thatcher. 2010. “A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5 (8): 1285–88. doi:10.1097/JTO.0b013e3181e3a2d1.